Project Grant R36AG087310

Award Date 8/1/24
Completion Date 7/31/25
Dollars Obligated $103K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90089, USA
Similar Awards
This Project Grant award from the National Institutes of Health's Aging Research program (CFDA 93.866) will support research to identify early transcriptional and pathological changes in brain regions vulnerable to Alzheimer's disease (AD). The $459,076 award, granted to Trustees of Boston University, will use single-nucleus RNA sequencing and targeted mass spectrometry to profile cell type-specific gene expression and tau/amyloid beta proteoforms in the transentorhinal cortex, entorhinal...
The National Institute on Aging (NIA) awarded a 5-year, $1,648,493 Project Grant (CFDA 93.866) to the Icahn School of Medicine at Mount Sinai to systematically investigate the molecular mechanisms of brain senescence in different molecular subtypes of Alzheimer's disease (AD). The project aims to identify and characterize senescent cells in major AD subtypes using advanced multi-omics and spatial transcriptomics techniques. The research team, which includes experts in translational senescence...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), provides $146,922 to The Trustees of Columbia University in the City of New York to conduct research on the impact of Alzheimer's disease on genetic signatures of hippocampal memory traces. The key objectives are to determine the gene expression landscape that distinguishes memory-encoding cells from memory-retrieval cells, and how this landscape changes with age and...
This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $3,845,311 to the University of California, San Diego (UCSD) to investigate the early determinants of Alzheimer's disease (AD) using age-equivalent neurons derived from mild cognitive impairment (MCI) patients. The project aims to better understand the convergence of risk factors, including polygenic variants and biological aging, on molecular pathways that initiate and...
This Project Grant award of $773,816, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to conduct cell-type-specific and spatial proteogenomics analysis of aberrant RNA splicing and misfolded proteins in Alzheimer's-related tauopathies. The research team from the University of California, Irvine will comparatively study new tau-directed Alzheimer's disease mouse models and human Alzheimer's brain tissues to generate single-cell spatial proteo-transcriptomics...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $128,321.00 to the Regents of the University of Michigan to systematically dissect the retrosplenial cortex (RSG) circuitry in preclinical Alzheimer's disease (AD) mouse models. The key objectives are to: Study biophysical changes in different RSG cell types in two AD mouse models and two age points, in both male and female mice, to generate a cell-type specific physiological map of RSG...
The National Institute on Aging (NIA), part of the National Institutes of Health within the Department of Health and Human Services, awarded a $2,567,371 Project Grant to The Trustees of Columbia University in the City of New York under the Aging Research program (CFDA 93.866). The grant will fund research from May 1, 2022 to April 30, 2025 to identify cell type-specific autonomous and non-autonomous interactions in Alzheimer's disease (AD) using induced pluripotent stem cell (iPSC) lines from...
This $3.6 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund research at the Icahn School of Medicine at Mount Sinai directed at understanding the role of glial cell interactions surrounding amyloid plaques in the progression of Alzheimer's disease. As part of the Aging Research program (CFDA 93.866), the three-year award will support investigation of how deletion of the Plexin-B1 gene impacts glial network formation and the...
This $107,948 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to enhance understanding of the biological signatures that distinguish subgroups of patients with Alzheimer's disease (AD). The key goals are to: Determine if AD subtypes can be identified solely using magnetic resonance imaging (MRI)-derived features through the application of machine learning algorithms. Integrate epigenetic profiles, including small non-coding RNA expression and DNA...
The University of California Irvine will receive $4,522,968 over three years from the National Institutes of Health National Institute on Aging under the Aging Research grant program (CFDA 93.866) to investigate the temporal, spatial and cellular dynamics of amyloid plaque deposition in Alzheimer's disease. The research will utilize cutting-edge biorthogonal non-canonical amino acid tagging technology and cell-specific Cre driver mouse lines to label the proteomes of specific cell types and...

CA1 CELL-TYPE SUSCEPTIBILITY IN ALZHEIMER'S - ABSTRACT ADVANCED NEUROIMAGING TECHNIQUES HAVE SHOWN THE IMPACTS OF ALZHEIMER'S DISEASE (AD) PATHOLOGY PROPAGATION AND THEIR STRUCTURAL REPERCUSSIONS IN THE BRAIN. RECENT STUDIES SHOW THAT UNIMPAIRED INDIVIDUALS WHO HAVE ADVANCED AMYLOID AND TAU PATHOLOGY IN THE MEDIAL TEMPORAL LOBE (MTL) ARE MORE AT RISK FOR DEVELOPING MILD COGNITIVE IMPAIRMENT (MCI). THESE DISCOVERIES SUGGEST THE PRESENCE OF VULNERABLE BRAIN REGIONS THAT SERVE AS AN INITIAL FOCAL POINT FOR THE SPREAD OF AD PATHOLOGY. RECENT DEVELOPMENTS IN CONNECTOMICS AND SPATIAL TRANSCRIPTOMICS NOW ALLOW US TO IDENTIFY INDIVIDUAL CELL TYPES WITHIN THE MTL AND INVESTIGATE THE SUBCELLULAR MOLECULAR CHANGES THAT OCCUR THROUGHOUT AD PROGRESSION. IDENTIFYING SUSCEPTIBLE CELL TYPES WITHIN MTL WILL REVEAL POTENTIAL TARGETS FOR EARLY TREATMENT INTERVENTION. WITHIN THE MTL, ENTORHINAL CORTEX (ENT) CONNECTIONS WITH CA1 IN THE HIPPOCAMPUS ARE PARTICULARLY AFFECTED BY AD AND RELATED TO COGNITIVE IMPAIRMENT. FROM CA1, IT IS BELIEVED THAT AMYLOID AND TAU PROPAGATE THROUGH NEURAL CIRCUITS TO OTHER BRAIN STRUCTURES, LEADING TO A NEURODEGENERATIVE CASCADE AS IT EXTENDS TO ADDITIONAL BRAIN REGIONS. ESTABLISHING AND CHARACTERIZING DISTINCT NEURONAL CHANGES IN CA1 PROJECTION NEURON CELL TYPES, IN THE PRESENCE OF AMYLOID, CAN REVEAL NOVEL TARGETS WITH THE AIM OF MITIGATING OR EVEN HALTING THE PROGRESSION OF AD AT ITS EARLIEST STAGES. WE HYPOTHESIZE THAT A NEURAL CIRCUIT FROM ENTORHINAL CA1 NEURONS THAT PROJECT TO OTHER MEMORY-RELATED BRAIN STRUCTURES ARE SPECIFICALLY SUSCEPTIBILITY POINTS TO AD. TO UNVEIL VULNERABLE CA1 NEURONS AND UNDERSTAND ALTERATIONS IN THEIR MORPHOLOGICAL CHARACTERISTICS, WE WILL USED ADVANCED VIRAL TRACING METHODS AND CUTTING-EDGE MICROSCOPY IMAGING TO IDENTIFY AND RECONSTRUCT 3D ENTCA1 CELL-TYPE SPECIFIC CIRCUITS TO ANALYZE DISTINCT PATHWAY CHANGES IN AD MOUSE MODELS. AFTER IDENTIFYING SUSCEPTIBLE CELL TYPES, WE WILL USE MERFISH SPATIAL TRANSCRIPTOMICS TO INVESTIGATE THE MOLECULAR CHANGES TO AD-RELEVANT GENES WITHIN CA1 NEURONS. OVERALL, THIS STUDY WILL ESTABLISH CELL TYPE SPECIFIC NEURAL CIRCUITS THAT ARE SUSCEPTIBLE TO AD PATHOLOGY AND REVEAL THE SUBCELLULAR RESPONSE OF THESE CELL TYPES THROUGHOUT THE PROGRESSION OF DISEASE.

Posted 7/30/24, 12:00 AM